180 Life Sciences’ Post

Mesothelioma is classified into four types, depending on where the tumors are located in the body. Patients are diagnosed with pleural, peritoneal, pericardial, or testicular mesothelioma. Learn more about the types of mesothelioma: https://lnkd.in/gkjUj7yD #MesotheliomaTypes #TypesofMesothelioma #MesotheliomaPatient

This recent study evaluated the efficacy of melflufen-dex compared to pomalidomide-dex in patients with multiple myeloma who are refractory to alkylators. The trial’s results contributed to the approval of melflufen-dex in Europe for patients who have undergone at least three previous lines of treatment, including those who have not undergone a transplant or did not progress after a transplant within three years. See more in this MEDtalk from PhD Fredrik Schjesvold, Forunder and Head of Oslo Myeloma Center. #Multiplemyeloma #myelooma #Hematology

This recent study evaluated the efficacy of melflufen-dex compared to pomalidomide-dex in patients with multiple myeloma who are refractory to alkylators. The trial’s results contributed to the approval of melflufen-dex in Europe for patients who have undergone at least three previous lines of treatment, including those who have not undergone a transplant or did not progress after a transplant within three years. See more in this MEDtalk from PhD Fredrik Schjesvold, Forunder and Head of Oslo Myeloma Center. #Multiplemyeloma #myelomatose #Hematology

This recent study evaluated the efficacy of melflufen-dex compared to pomalidomide-dex in patients with multiple myeloma who are refractory to alkylators. The trial’s results contributed to the approval of melflufen-dex in Europe for patients who have undergone at least three previous lines of treatment, including those who have not undergone a transplant or did not progress after a transplant within three years. See more in this MEDtalk from PhD Fredrik Schjesvold, Forunder and Head of Oslo Myeloma Center. #Multiplemyeloma #myelomatose #Hematology

This case involved a middle-aged male patient diagnosed with carcinoma in situ of the bladder. At the time of diagnosis, doctors found no signs of metastasis… Want to read more? Check out the entire case study on our website! https://lnkd.in/eWYK7pr Have a new case going to trial? Call 800-747-9782 or email [email protected]! #litigation #medical #medicalmalpractice #personalinjury #casestudy #trialexhibits #triallawyer #medicalillustration #illustration #medmal #legaleducation #trialconsultation #juryeducation #defensecase #personalinjury #datavisualization #trialprep #legalinnovation #legaltech #2danimation #medicalaccuracy

This recent study evaluated the efficacy of melflufen-dex compared to pomalidomide-dex in patients with multiple myeloma who are refractory to alkylators. The trial’s results contributed to the approval of melflufen-dex in Europe for patients who have undergone at least three previous lines of treatment, including those who have not undergone a transplant or did not progress after a transplant within three years. See more in this MEDtalk from PhD Fredrik Schjesvold, Forunder and Head of Oslo Myeloma Center. #Multiplemyeloma #myelom #Hematology

In this cohort study of patients undergoing resection of locally recurrent extremity/trunk soft tissue sarcoma, higher local recurrence growth rate was associated with higher risk of disease-specific death. https://ja.ma/3TfW7Za

Initial clinical activity score (CAS) can help predict response to teprotumumab treatment for thyroid eye disease (TED), according to new research from Journal of Neuro-Ophthalmology (NANOS - North American Neuro-Ophthalmology Society). In particular, the study shows the association with baseline clinical activity score and teprotumumab’s effect on diplopia. Right and left gaze horizontal prism deviation can also help predict teprotumumab treatment response, according to the researchers. Read more: https://brnw.ch/21wEUol #ClinicalActivityScore #CAS #Teprotumumab #ThyroidEyeDisease #TED #Diplopia #Ophthalmology #EyeHealth #Ophthalmologist #EyeCare

A new study highlights the independent prognostic importance of intramyocardial hemorrhage in managing risk after #STEMI after researchers associated microvascular injury with future adverse outcomes only in patients with a hemorrhagic phenotype. Read more on #CRTonline. https://ow.ly/XNzg50Sa3GM #cardiacnurse #cardiologists #cardiology #cardiologyfellow #cardiologyfellows #cardiologynurse #cardiologynurses #cathlab #cathlabnurse #cathlabtech #interventionalcardiologists #interventionalcardiology #interventionalcardiologyfellow #interventionalcardiologyfellows #MCRN #medicalequity

Are there potential Interactions between SGLT2 Inhibitors & Intravenous Iron in Heart Failure? What’s happening regarding HIF-PHIs for anemia management in Chronic kidney disease? Join the discussion during Plenary Session 6 at #eSPACECRM2024. An in-depth look at Anemia & Iron Deficiency & clinical implications. Register: https://ow.ly/NsEp50Qz2s2 #eSPACECRM2024 #Diabetes #T2D #KidneyDisease #HeartFailure #CKD #Cardiology #MedEdgs